Cook, Joselle http://orcid.org/0000-0001-5335-9533
Gonsalves, Wilson I.
Gertz, Morie A. http://orcid.org/0000-0002-3853-5196
Visram, Alissa http://orcid.org/0000-0002-7201-4642
Warsame, Rahma
Lacy, Martha Q.
Dispenzieri, Angela http://orcid.org/0000-0001-8780-9512
Dingli, David http://orcid.org/0000-0001-7477-3004
Kapoor, Prashant http://orcid.org/0000-0002-4342-364X
Kourelis, Taxiarchis V. http://orcid.org/0000-0001-8573-9434
Hayman, Suzanne R.
Kyle, Robert A.
Muchtar, Eli http://orcid.org/0000-0003-2210-2174
Kumar, Shaji K. http://orcid.org/0000-0001-5392-9284
Hogan, William J. http://orcid.org/0000-0002-5841-4105
Jacob, Eapen K.
Buadi, Francis K. http://orcid.org/0000-0003-3214-0203
Article History
Received: 1 July 2021
Revised: 19 March 2022
Accepted: 23 March 2022
First Online: 2 April 2022
Competing interests
: AD: Alnylam: Research Funding; Celgene: Research Funding; Janssen: Research Funding; Takeda: Research Funding; Intellia: Research Funding; Pfizer: Research Funding. DD: Grant/Research funding from Juno, Celgene. MG: personal fees from Ionis/Akcea, personal fees from Alnylam, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, grants and personal fees from Spectrum, personal fees from Annexon, personal fees from Appellis, personal fees from Amgen, personal fees from Medscape, personal fees from Physicians Education Resource, personal fees for Data Safety Monitoring board from Abbvie, and Celgene personal fees from Research to Practice, Speaker fees from Johnson and Johnson; Speaker fees from Medscape, Speaker fees DAVA oncology; Advisory Board for Pharmacyclics Advisory Board for Proclara outside the submitted work; Development of educational materials for i3Health. Educational Program development i3Health. Royalties from Springer Publishing. Grant Funding Amyloidosis Foundation; International Waldenstrom Foundation. NCI SPORE MM SPORE 5P50 CA186781-04 PK: Research funding (Takeda, Celgene, and Amgen). SK: Consulting or advisory Role with Takeda, Janssen Oncology, Amgen, AbbVie, Merck, Celgene, Genentech/Roche, Oncopeptides, Kite, a Gilead company, Genecentrix, Molecular Partners, Bluebird Bio, Cellectar and research Funding: Celgene, Takeda, AbbVie, Novartis, Sanofi, Janssen Oncology, Merck, Kite, a Gilead company, MedImmune, Roche/Genentech, TeneoBio, CARsgen Therapeutics. MQL: Research funding (Celgene)
: The study was conducted in accordance with the Declaration of Helsinki.